Nexalin Technology Study Shows Reduced Self-Injury in Adolescents Using Brain Stimulation Device
Nexalin Technology, Inc. has published a peer-reviewed study in BMC Psychiatry highlighting the effects of its Deep Intracranial Frequency Stimulation (DIFS) technology on adolescents with non-suicidal self-injury (NSSI). The study involved six female adolescent patients who underwent 21 days of 77.5 Hz, 15 mA stimulation using Nexalin's device. Results indicated statistically significant reductions in self-injury behaviors and depressive symptoms, along with changes in brain-network activity and connectivity. The study also reported improvements in anxiety and sleep quality measures, with no significant adverse effects observed. Nexalin's CEO, Mark White, emphasized the potential of the technology to offer drug-free alternatives in mental health treatment, supporting higher efficacy and enhanced outcomes in treatment-resistant populations.